Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT05024552
Title Vyxeos Plus Gilteritinib in Relapsed or Refractory, FLT3-Mutated AML
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements Yes
Sponsors H. Lee Moffitt Cancer Center and Research Institute
Indications
Therapies
Age Groups: senior | adult
Covered Countries USA

Additional content available in CKB BOOST